You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

CLINICAL TRIALS PROFILE FOR DURACLON


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Duraclon

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00349921 ↗ Clonidine Versus Adenosine to Treat Neuropathic Pain Completed National Institute of Neurological Disorders and Stroke (NINDS) Phase 2 2004-08-01 The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain.
NCT00349921 ↗ Clonidine Versus Adenosine to Treat Neuropathic Pain Completed Wake Forest School of Medicine Phase 2 2004-08-01 The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain.
NCT00349921 ↗ Clonidine Versus Adenosine to Treat Neuropathic Pain Completed Wake Forest University Health Sciences Phase 2 2004-08-01 The purpose of this study is to determine the effects of clonidine and adenosine on nerve pain.
NCT00510016 ↗ Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome Completed Johns Hopkins University Phase 2 2002-07-01 To test the hypothesis that the combination of the tincture of opium (DTO) and clonidine will be more effective in treating infants with neonatal abstinence syndrome (opioid withdrawal) than tincture of opium (DTO) alone.
NCT00510016 ↗ Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome Completed National Institute on Drug Abuse (NIDA) Phase 2 2002-07-01 To test the hypothesis that the combination of the tincture of opium (DTO) and clonidine will be more effective in treating infants with neonatal abstinence syndrome (opioid withdrawal) than tincture of opium (DTO) alone.
NCT00678379 ↗ Pediatric Tonsillectomy Pain Reduction Study Completed Vanderbilt University Medical Center Phase 3 2008-04-01 Tonsillectomy is associated with a significant decrease quality of life in children secondary to pain, which is worsened with swallowing. The objective of the current study is to conduct a prospective, double-blind, placebo-controlled, randomized clinical trial using a pre-tonsillectomy infiltration of the tonsillar fossa comparing three treatment regimens in reducing post-tonsillectomy morbidity (i.e. pain, poor oral intake): 1) Placebo (saline injection) 2) bupivacaine (0.5%) + lidocaine (1%), 3) bupivacaine (0.5%) + lidocaine (1%) + clonidine (25 µg).
NCT01360450 ↗ Clonidine to Treat Iatrogenic-induced Opioid Dependence in Infants Terminated National Institute on Drug Abuse (NIDA) Phase 2/Phase 3 2011-07-01 Thousands of critically ill infants (and children) are exposed to opioids and benzodiazepines to achieve sedation and analgesia as part of routine care in neonatal and pediatric intensive care units. While the use of these agents are undisputedly beneficial in reducing pain and anxiety, improving ventilation, reducing pulmonary vascular resistance and improving outcomes; the consequence is often the development of tolerance and physiologic dependence - similar to prenatal exposure from these same classes of drugs. The investigators have recently reported the results of randomized placebo control trial showing that the addition of clonidine (central alpha 2 agonist) to tapering doses of opioids was efficacious and safe in treating opioid dependence in infants who had moderate to severe neonatal abstinence syndrome from prenatal drug exposure to opioids. Currently, the investigators propose to perform a double-blind, randomized placebo control trial in a cohort of critically ill infants without prenatal drug exposure at Johns Hopkins Hospital to test the overall hypothesis that early addition of clonidine to a cohort of critically ill neonates on mechanical ventilation who are receiving opioids and benzodiazepines for analgesia and sedation will be efficacious and safe in reducing both the incidence and severity of withdrawal symptoms (NICU-NAS); as well as, reducing the time to complete sedative and analgesic drug detoxification. The hypothesis will be tested by addressing 2 specific aims that will determine: 1) the efficacy and safety of clonidine in critically ill infants, and 2) pharmacokinetics and pharmacodynamics using population-based pharmacokinetics in this vulnerable infant population who have only been exposed to these drugs as part of their routine care. Many "standard of care practices" are incorporated in neonatal and pediatric care prior to evidence based studies. This proposal will fill a much needed gap in translating what the investigators have learned about basic mechanisms mediating dependence and withdrawal to proven therapies for vulnerable pediatric populations.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Duraclon

Condition Name

Condition Name for Duraclon
Intervention Trials
Neonatal Abstinence Syndrome 2
Postoperative Pain 2
Labor Pain 1
Mechanical Ventilation Complication 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Duraclon
Intervention Trials
Neonatal Abstinence Syndrome 2
Pain, Postoperative 2
Neuralgia 1
Labor Pain 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Duraclon

Trials by Country

Trials by Country for Duraclon
Location Trials
United States 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Duraclon
Location Trials
Maryland 3
Pennsylvania 1
New York 1
Tennessee 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Duraclon

Clinical Trial Phase

Clinical Trial Phase for Duraclon
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Duraclon
Clinical Trial Phase Trials
Completed 6
Terminated 2
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Duraclon

Sponsor Name

Sponsor Name for Duraclon
Sponsor Trials
Johns Hopkins University 3
National Institute on Drug Abuse (NIDA) 2
Gauda, Estelle B., M.D. 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Duraclon
Sponsor Trials
Other 14
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.